加入收藏 | 设为首页 | 联系我们

产品搜索

相关文章

联系我们

联系人:蒋经理
电话:86-25-86880024
号码:86-25-86880024
手机:18066071954
地址:南京市雨花区长虹路222号
Email: duhaitao@cobioer.com

产品展示 / PRODUCTS
药靶细胞株 > kinase激酶细胞株 > CBP73192SLC34A2-ROS1 G2032R/BaF3

SLC34A2-ROS1 G2032R/BaF3
名称 SLC34A2-ROS1 G2032R/BaF3
型号 CBP73192
报价
特点 SLC34A2-ROS1 [G2032R]/BaF3,母细胞:BaF3,冻存条件:90% FBS+10% DMSO;培养基:RPMI-1640+10% FBS+1 ug/ml puromycin
  • 详细内容
" _ue_custom_node_="true">
CBP73192
I. Introduction

Cell Line Name:

SLC34A2-ROS1 [G2032R]/BaF3

Host Cell:

Ba/F3

Stability:16 passages

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10% FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative

 
II.Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).
In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients&mdash;a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient&mdash;with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazi&egrave;res et al. 2015).
Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.
ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).

 
III. Representative Data

1. WB of SLC34A2-ROS1 [G2032R]/BaF3expression

CBP73192 WB.png

 

Figure 1. Protein Expression of ROS1 detected by antibody

 

2.Sanger Sequencing of SLC34A2-ROS1 Fusion and G2032R mutation

Figure 2. SLC34A2-ROS1 Fusion

CBP73192 sanger2.png

Figure 3. ROS1 p.G2032R

 

3. Anti-proliferation assay

CBP73192 fig.png

Figure 4. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1 [G2032R]/BaF3 Stable Cell Line.


如果你对CBP73192SLC34A2-ROS1 G2032R/BaF3感兴趣,想了解更详细的产品信息,填写下表直接与厂家联系:


留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
QQ在线客服
电话咨询
  • 25-86880024
  • 手机:18066071954

化工仪器网

推荐收藏该企业网站
扫一扫访问手机站扫一扫访问手机站
访问手机站